Keys to Optimizing Multidisciplinary cGVHD Care

Chronic graft-versus-host disease is a heterogeneous disease characterized by inflammatory and/or fibrotic manifestations, where a multidisciplinary team approach is necessary for optimal patient care—but what are the keys to successful collaborative management of this condition? Our host, Dr. Dennis Kim, takes a deep look into this topic with Dr. Kristjan Paulson, Hematologist within the Leukemia and Blood and Marrow Transplant Disease Site Groups at CancerCare Manitoba. He is also the Past-President of Cell Therapy Transplant Canada (CTTC) and leads the Canadian Blood and Marrow Transplant Group Registry as Primary Investigator and Scientific Director.

This episode discusses the importance of collaborative care and the roles of various multidisciplinary team members in addressing the clinical complexities of chronic graft-versus-host disease (cGVHD). Our experts also touch how organizations such as the CTTC can be a helpful resource for providers managing GVHD, as well as strategies to create local networks of sub-specialists, where providers can learn from each other in the hopes of providing best care for improved patient outcomes. Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Dennis Kim:

• Direct financial relationship including receipt of honoraria: Novartis, Sanofi, Pfizer, Jazz, Paladin. Membership on advisory boards or speakers’ bureaus: Novartis, Sanofi, Jazz, Paladin. Funded grants, research or clinical trials: Novartis, Sanofi, Pfizer, Paladin.

Dr. Kristjan Paulson:

• Membership on advisory boards or speakers’ bureaus: Sanofi, Amgen, Pfizer, Novartis, Astellas, Jazz, AbbVie. Funded grants, research or clinical trials: Sanofi, Amgen, Pfizer, Novartis, Astellas, Jazz, AbbVie.

MAT-CA-2301194 App Aug 2023